Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed\* Hodgkin lymphoma~  * Clinical stage IA, IB, IIA, or IIB disease according to the modified Ann Arbor Staging Classification system~ * Subclassified according to the WHO modification of the Rye Classification~ * E extension allowed provided all other criteria have been met NOTE: \*Pathology materials must be submitted within 60 days of study registration. Core-needle biopsies are acceptable provided they contain adequate tissue for primary diagnosis and immunophenotyping. Fine-needle aspirates not allowed. If multiple specimens are available, submit the most recent.~* No nodular lymphocyte-predominant Hodgkin lymphoma~* No mediastinal mass \> 0.33 maximum intrathoracic diameter by standing postero-anterior chest x-ray or peripheral or retroperitoneal adenopathy \> 10 cm in its largest diameter~* Measurable disease by physical examination or imaging studies~  * Any tumor mass measurable in two dimensions and \> 1 cm (or 1.5 cm if 0.5 cm slices are used, as in spiral CT scans) allowed~ * Lesions that are considered intrinsically non-measurable include:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusion~   * Lymphangitis cutis/pulmonis~   * Abdominal masses that are not confirmed and followed by imaging techniques~   * Cystic lesions~   * Lesions that are situated in a previously irradiated area~PATIENT CHARACTERISTICS:~* Performance status 0-2~* ANC ≥ 1,000/μL~* Platelet count ≥ 100,000/μL~* Serum creatinine ≤ 2 mg/dL~* Bilirubin ≤ 2 mg/dL~* AST ≤ 2 times upper limit of normal~* LVEF normal by ECHO or MUGA~* DLCO ≥ 60% with no symptomatic pulmonary disease~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Patients with known HIV allowed provided they have CD4 counts ≥ 350/mcL~  * Patients must not have multi-drug resistant HIV infections (i.e., concurrent AIDS-defining conditions)~ * An HIV test is required for patients with a history of IV drug abuse or any behavior associated with an increased risk of HIVinfection~* No currently active second malignancy other than nonmelanoma skin cancers~  * Patients are not considered to have a currently active malignancy provided they have completed therapy and are considered by their physician to be at \< 30% risk of relapse~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy or radiotherapy for Hodgkin lymphoma~  * 1 course of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) allowed and will be considered the first course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy and F-18 PET/CT) (Type: EXPERIMENTAL): See Detailed Description

Based on this trial design, predict the completion outcome and termination type (if applicable).